Search

Your search keyword '"TAMAI, Toshiyuki"' showing total 256 results

Search Constraints

Start Over You searched for: Author "TAMAI, Toshiyuki" Remove constraint Author: "TAMAI, Toshiyuki"
256 results on '"TAMAI, Toshiyuki"'

Search Results

4. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyBiomarker Analysis Following Lenvatinib in Unresectable HCC

5. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

6. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

7. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

9. Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.

11. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

12. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

18. A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.

20. 'Fair M&A Guidelines' and MBOs

25. Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors

26. 'Fair M&A Guidelines' and Freezeout Transactions(2)

27. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

29. Helically aligned fused carbon hollow nanospheres with chiral discrimination ability

31. M&A Transactions and Injunctive Relief

34. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.

37. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma

42. M&A Transactions and Injunctive Relief(2)

43. Generation of polyphenylene radical cations and their cosensitization ability in the 9,10-dicyanoanthracene-sensitized photochemical chain reactions of 1,2-bis(4-methoxyphenyl)cyclopropane

44. Photooxygenation of 1,omega-bis(diarylethenyl)alkanes via photoinduced electron-transfer: formation of 1,4-radical cations and its trapping by molecular dioxygen

46. Salt effect of the 9,10-dicyanoanthracene-sensitized photooxygenation of 1,2-diarylcyclopropanes and the photodecomposition of 3,5-diaryl-1,2-dioxolanes

47. Insertion of nitrogen oxide and nitrosonium ion into the cyclopropane ring: a new route to 2-isoxazolines and its mechanistic studies

48. Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).

49. Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study

50. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Catalog

Books, media, physical & digital resources